Search

Your search keyword '"Janjigian, Yelena"' showing total 23 results
Start Over Author "Janjigian, Yelena" Journal annals of surgery
23 results on '"Janjigian, Yelena"'

1. Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study

Author

Cowzer, Darren, Wu, Abraham Jing-Ching, Sihag, Smita, Walch, Henry S., Park, Bernard J., Jones, David R., Gu, Ping, Maron, Steven B., Sugarman, Ryan, Chalasani, Sree Bhavani, Shcherba, Marina, Capanu, Marinela, Chou, Joanne F., Choe, Jennie K., Nosov, Anton, Adusumilli, Prasad S., Yeh, Randy, Tang, Laura H., Ilson, David H., Janjigian, Yelena Y., Molena, Daniela, and Ku, Geoffrey Y.

Published
2023
Full Text
View/download PDF

2. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction

Author

Nakauchi, Masaya, primary, Walch, Henry S., additional, Nussenzweig, Samuel, additional, Carr, Rebecca, additional, Vos, Elvira, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Janjigian, Yelena, additional, Wu, Abraham, additional, Tang, Laura, additional, Shah, Pari, additional, Jones, David R., additional, Coit, Dan, additional, Strong, Vivian E., additional, Molena, Daniela, additional, and Sihag, Smita, additional

Published
2024
Full Text
View/download PDF

4. Waiting to Operate: The Risk of Salvage Esophagectomy

Author

Boerner, Thomas, Harrington, Caitlin, Tan, Kay See, Adusumilli, Prasad S., Bains, Manjit S., Bott, Matthew J., Downey, Robert J., Huang, James, Ilson, David H., Isbell, James M., Janjigian, Yelena Y., Park, Bernard J., Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Wu, Abraham J., Jones, David R., and Molena, Daniela

Published
2023
Full Text
View/download PDF

12. Waiting to Operate

Author

Boerner, Thomas, primary, Harrington, Caitlin, additional, Tan, Kay See, additional, Adusumilli, Prasad S., additional, Bains, Manjit S., additional, Bott, Matthew J., additional, Downey, Robert J., additional, Huang, James, additional, Ilson, David, additional, Isbell, James M., additional, Janjigian, Yelena Y., additional, Park, Bernard J., additional, Rocco, Gaetano, additional, Rusch, Valerie W., additional, Sihag, Smita, additional, Wu, Abraham J., additional, Jones, David R., additional, and Molena, Daniela, additional

Published
2023
Full Text
View/download PDF

14. A Novel Microbiome Signature in Gastric Cancer

Author

Abate, Miseker, primary, Vos, Elvira, additional, Gonen, Mithat, additional, Janjigian, Yelena Y., additional, Schattner, Mark, additional, Laszkowska, Monika, additional, Tang, Laura, additional, Maron, Steven B., additional, Coit, Daniel G., additional, Vardhana, Santosh, additional, Vanderbilt, Chad, additional, and Strong, Vivian E., additional

Published
2022
Full Text
View/download PDF

15. Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy

Author

Vos, Elvira L., primary, Maron, Steven B., additional, Krell, Robert W., additional, Nakauchi, Masaya, additional, Fiasconaro, Megan, additional, Capanu, Marinela, additional, Walch, Henry S., additional, Chatila, Walid K., additional, Schultz, Nikolaus, additional, Ilson, David H., additional, Janjigian, Yelena Y., additional, Ku, Geoffrey Y., additional, Yoon, Sam S., additional, Coit, Daniel G., additional, Vanderbilt, Chad M., additional, Tang, Laura H., additional, and Strong, Vivian E., additional

Published
2022
Full Text
View/download PDF

16. Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma.

Author

Carr, Rebecca A., Hsu, Meier, Harrington, Caitlin A., Tan, Kay See, Bains, Manjit S., Bott, Matthew J., Ilson, David H., Isbell, James M., Janjigian, Yelena Y., Maron, Steven B., Park, Bernard J., Rusch, Valerie W., Sihag, Smita, Wu, Abraham J., Jones, David R., Ku, Geoffrey Y., and Molena, Daniela

Abstract

Objective: To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC. Summary of Background Data: nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy. Methods: We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with ≥90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan–Meier method and evaluated using the log-rank test and extended Cox regression. Results: In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group. Conclusions: Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

Author

Carr, Rebecca A., primary, Hsu, Meier, additional, Harrington, Caitlin A., additional, Tan, Kay See, additional, Bains, Manjit S., additional, Bott, Matthew J., additional, Ilson, David H., additional, Isbell, James M., additional, Janjigian, Yelena Y., additional, Maron, Steven B., additional, Park, Bernard J., additional, Rusch, Valerie W., additional, Sihag, Smita, additional, Wu, Abraham J., additional, Jones, David R., additional, Ku, Geoffrey Y., additional, and Molena, Daniela, additional

Published
2021
Full Text
View/download PDF

18. A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma.

Author

Sihag, Smita, Nobel, Tamar, Hsu, Meier, Tan, Kay See, Carr, Rebecca, Janjigian, Yelena Y., Tang, Laura H., Wu, Abraham J., Bott, Matthew J., Isbell, James M., Bains, Manjit S., Jones, David R., and Molena, Daniela

Abstract

Objective: We sought to determine the extent of lymphadenectomy that optimizes staging and survival in patients with locally advanced EAC treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Summary of Background Data: Several studies have found that a more extensive lymphadenectomy leads to better disease-specific survival in patients treated with surgery alone. Few studies, however, have investigated whether this association exists for patients treated with neoadjuvant chemoradiotherapy. Methods: We examined our prospective database and identified patients with EAC treated with neoadjuvant chemoradiotherapy followed by esophagectomy between 1995 and 2017. Overall survival (OS) and DFS were estimated using Kaplan-Meier methods, and a multivariable Cox proportional hazards model was used to identify independent predictors of OS and DFS. The relationship between the total number of nodes removed and 5-year OS or DFS was plotted using restricted cubic spline functions. Results: In total, 778 patients met the inclusion criteria. The median number of excised nodes was 21 (interquartile range, 16–27). A lower number of excised lymph nodes was independently associated with worse OS and DFS (OS: hazard ratio, 0.98; confidence interval, 0.97–1.00; P = 0.013; DFS: hazard ratio, 0.99; confidence interval, 0.98–1.00; P = 0.028). Removing 25 to 30 lymph nodes was associated with a 10% risk of missing a positive lymph node. Both OS and DFS improved with up to 20 to 25 lymph nodes removed, regardless of treatment response. Conclusions: The optimal extent of lymphadenectomy to enhance both staging and survival after chemoradiotherapy, regardless of treatment response, is approximately 25 lymph nodes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma

Author

Sihag, Smita, primary, Nobel, Tamar, additional, Hsu, Meier, additional, Tan, Kay See, additional, Carr, Rebecca, additional, Janjigian, Yelena Y., additional, Tang, Laura H., additional, Wu, Abraham J., additional, Bott, Matthew J., additional, Isbell, James M., additional, Bains, Manjit S., additional, Jones, David R., additional, and Molena, Daniela, additional

Published
2020
Full Text
View/download PDF

20. Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma

Author

Sihag, Smita, primary, Nobel, Tamar, additional, Hsu, Meier, additional, De La Torre, Sergio, additional, Tan, Kay See, additional, Janjigian, Yelena Y., additional, Ku, Geoffrey Y., additional, Tang, Laura H., additional, Wu, Abraham J., additional, Maron, Steven B., additional, Bains, Manjit S., additional, Jones, David R., additional, and Molena, Daniela, additional

Published
2020
Full Text
View/download PDF

23. Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma

Author

Hernandez, Jonathan M., primary, Beylergil, Volkan, additional, Goldman, Debra A., additional, van Beek, Elke, additional, Gonen, Mithat, additional, Tang, Laura, additional, Downey, Robert, additional, Rizk, Nabil, additional, Shah, Manish, additional, Strong, Vivian, additional, Janjigian, Yelena, additional, Schöder, Heiko, additional, and Coit, Daniel G., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results